In Brief for February 9, 2022

Multidisciplinary Tumor Boards: Six Eyes See More than Two

Unplanned Hospital Care in Patients With NSCLC

Predicting Early Weight Loss in Radiotherapy

Determining the Most Effective Chemotherapy Regimen in Patients With Advanced KRAS-Mutated NSCLC: the NVALT22 study

Novel Targets and Therapies: KEAP1- and NFE2L2-Mutant Squamous Cell Lung Cancer

Role of Liquid Biopsy in the Clinic Growing

Targeting Angiogenesis in Mesothelioma: Insights From MAPS and RAMES

A New Standard of Care in EGFR-Positive NSCLC Unresponsive to TKIs?

The OncoKB Precision Oncology Knowledge Base: A Q&A with Dr. Debyani Chakravarty

US FDA greenlights nivolumab for use before surgery for NSCLC

Tumor Growth Rate as a Guide for Precision Lung Cancer Therapy